Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Growth (Status and Outlook) 2025-2031--LP INFORMATION, INC.

Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Growth (Status and Outlook) 2025-2031

Product Code: 1561683

Industry: Medical Care

Published: May 15,2025

Pages: 112

Delivery Time: 2-3 business days

Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Growth (Status and Outlook) 2025-2031

Product Code: 1561683

Industry: Medical Care

Published: May 15,2025

Pages: 112

Delivery Time: 2-3 business days

Select A Format

Single User License

USD3660

Multi Users License

USD5490

Corporate Users License

USD7320

Buy Now

Add To Cart

Or More Options：

PDF Download

Sample Request

Custom Request

Provide market analysis and obtain sources of data reports

Description

According to this study, the global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO market size will reach US$ million by 2031.

As an innovative and advanced biomedical method, Antibody-Oligonucleotide Conjugates (AOCs) have attracted much attention in the industry, and more and more domestic and foreign biopharmaceutical companies have participated in the research and development and application of AOCs. Because AOC combines the advantages of oligonucleotide technology and antibodies, it is believed to have the potential to provide precise targeted therapy and is expected to bring changes to the biomedical field. AOC CDMOs are companies that specialize in providing development and production services for antibody-oligonucleotide drug conjugates. These companies usually have professional technical capabilities and facilities to meet customers' needs in new drug research and development and production.

United States market for Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO players cover Porton Pharma Solutions, Lonza Group Ltd., BOC Sciences, Asymchem Laboratories (Tianjin) Co., Ltd., PixelBiosciences GmbH, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Industry Forecast” looks at past sales and reviews total world Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO sales for 2025 through 2031. With Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO industry.

This Insight Report provides a comprehensive analysis of the global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO.

This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type:

API

    Finished Product

Segmentation by Application:

    Commercial Use

    Scientific Research

This report also splits the market by region:

    Americas

    United States

    Canada

    Mexico

    Brazil

    APAC

    China

    Japan

    Korea

    Southeast Asia

    India

    Australia

    Europe

    Germany

    France

UK

    Italy

    Russia

    Middle East & Africa

    Egypt

    South Africa

    Israel

    Turkey

    GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

    Porton Pharma Solutions

    Lonza Group Ltd.

    BOC Sciences

    Asymchem Laboratories (Tianjin) Co., Ltd.

    PixelBiosciences GmbH

    3PBIOVIAN

    Genscript

    MabPlex international)

    WuXi XDC

    ChemExpress

    Abzena

Table Of Contents

1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
    1.8 Market Estimation Caveats

2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size (2020-2031)
        2.1.2 Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031)
        2.1.3 World Current & Future Analysis for Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO by Country/Region (2020, 2024 & 2031)
    2.2 Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Segment by Type
        2.2.1 API
        2.2.2 Finished Product
    2.3 Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Type
        2.3.1 Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031)
        2.3.2 Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Type (2020-2025)
    2.4 Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Segment by Application
        2.4.1 Commercial Use
        2.4.2 Scientific Research
    2.5 Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Application
        2.5.1 Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031)
        2.5.2 Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Application (2020-2025)

3 Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Player
    3.1 Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Player
        3.1.1 Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue by Player (2020-2025)
        3.1.2 Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue Market Share by Player (2020-2025)
    3.2 Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Key Players Head office and Products Offered
    3.3 Market Concentration Rate Analysis
        3.3.1 Competition Landscape Analysis
        3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
    3.4 New Products and Potential Entrants
    3.5 Mergers & Acquisitions, Expansion

4 Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO by Region
    4.1 Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Region (2020-2025)
    4.2 Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Annual Revenue by Country/Region (2020-2025)
    4.3 Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth (2020-2025)
    4.4 APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth (2020-2025)
    4.5 Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth (2020-2025)
    4.6 Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth (2020-2025)

5 Americas
    5.1 Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Country (2020-2025)
    5.2 Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Type (2020-2025)
    5.3 Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Application (2020-2025)
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil

6 APAC
    6.1 APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Region (2020-2025)
    6.2 APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Type (2020-2025)
    6.3 APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Application (2020-2025)
    6.4 China
    6.5 Japan
    6.6 South Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia

7 Europe
    7.1 Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Country (2020-2025)
    7.2 Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Type (2020-2025)
    7.3 Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Application (2020-2025)
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia

8 Middle East & Africa
    8.1 Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO by Region (2020-2025)
    8.2 Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Type (2020-2025)
    8.3 Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Application (2020-2025)
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries

9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends

10 Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Forecast
    10.1 Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast by Region (2026-2031)
        10.1.1 Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast by Region (2026-2031)
        10.1.2 Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.1.3 APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.1.4 Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.1.5 Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
    10.2 Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast by Country (2026-2031)
        10.2.1 United States Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.2.2 Canada Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.2.3 Mexico Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.2.4 Brazil Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
    10.3 APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast by Region (2026-2031)
        10.3.1 China Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Forecast
        10.3.2 Japan Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.3.3 Korea Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.3.4 Southeast Asia Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.3.5 India Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.3.6 Australia Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
    10.4 Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast by Country (2026-2031)
        10.4.1 Germany Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.4.2 France Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.4.3 UK Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.4.4 Italy Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.4.5 Russia Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
    10.5 Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast by Region (2026-2031)
        10.5.1 Egypt Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.5.2 South Africa Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.5.3 Israel Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
        10.5.4 Turkey Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast
    10.6 Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast by Type (2026-2031)
    10.7 Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast by Application (2026-2031)
        10.7.1 GCC Countries Market Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Forecast

11 Key Players Analysis
    11.1 Porton Pharma Solutions
        11.1.1 Porton Pharma Solutions Company Information
        11.1.2 Porton Pharma Solutions Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
        11.1.3 Porton Pharma Solutions Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.1.4 Porton Pharma Solutions Main Business Overview
        11.1.5 Porton Pharma Solutions Latest Developments
    11.2 Lonza Group Ltd.
        11.2.1 Lonza Group Ltd. Company Information
        11.2.2 Lonza Group Ltd. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
        11.2.3 Lonza Group Ltd. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.2.4 Lonza Group Ltd. Main Business Overview
        11.2.5 Lonza Group Ltd. Latest Developments
    11.3 BOC Sciences
        11.3.1 BOC Sciences Company Information
        11.3.2 BOC Sciences Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
        11.3.3 BOC Sciences Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.3.4 BOC Sciences Main Business Overview
        11.3.5 BOC Sciences Latest Developments
    11.4 Asymchem Laboratories (Tianjin) Co., Ltd.
        11.4.1 Asymchem Laboratories (Tianjin) Co., Ltd. Company Information
        11.4.2 Asymchem Laboratories (Tianjin) Co., Ltd. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
        11.4.3 Asymchem Laboratories (Tianjin) Co., Ltd. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.4.4 Asymchem Laboratories (Tianjin) Co., Ltd. Main Business Overview
        11.4.5 Asymchem Laboratories (Tianjin) Co., Ltd. Latest Developments
    11.5 PixelBiosciences GmbH
        11.5.1 PixelBiosciences GmbH Company Information
        11.5.2 PixelBiosciences GmbH Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
        11.5.3 PixelBiosciences GmbH Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.5.4 PixelBiosciences GmbH Main Business Overview
        11.5.5 PixelBiosciences GmbH Latest Developments
    11.6 3PBIOVIAN
        11.6.1 3PBIOVIAN Company Information
        11.6.2 3PBIOVIAN Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
        11.6.3 3PBIOVIAN Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.6.4 3PBIOVIAN Main Business Overview
        11.6.5 3PBIOVIAN Latest Developments
    11.7 Genscript
        11.7.1 Genscript Company Information
        11.7.2 Genscript Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
        11.7.3 Genscript Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.7.4 Genscript Main Business Overview
        11.7.5 Genscript Latest Developments
    11.8 MabPlex international)
        11.8.1 MabPlex international) Company Information
        11.8.2 MabPlex international) Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
        11.8.3 MabPlex international) Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.8.4 MabPlex international) Main Business Overview
        11.8.5 MabPlex international) Latest Developments
    11.9 WuXi XDC
        11.9.1 WuXi XDC Company Information
        11.9.2 WuXi XDC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
        11.9.3 WuXi XDC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.9.4 WuXi XDC Main Business Overview
        11.9.5 WuXi XDC Latest Developments
    11.10 ChemExpress
        11.10.1 ChemExpress Company Information
        11.10.2 ChemExpress Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
        11.10.3 ChemExpress Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.10.4 ChemExpress Main Business Overview
        11.10.5 ChemExpress Latest Developments
    11.11 Abzena
        11.11.1 Abzena Company Information
        11.11.2 Abzena Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
        11.11.3 Abzena Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.11.4 Abzena Main Business Overview
        11.11.5 Abzena Latest Developments

12 Research Findings and Conclusion

List Of Tables

List of Tables
 Table 1. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
 Table 2. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
 Table 3. Major Players of API
 Table 4. Major Players of Finished Product
 Table 5. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
 Table 6. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Type (2020-2025) & ($ millions)
 Table 7. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Type (2020-2025)
 Table 8. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
 Table 9. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Application (2020-2025) & ($ millions)
 Table 10. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Application (2020-2025)
 Table 11. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue by Player (2020-2025) & ($ millions)
 Table 12. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue Market Share by Player (2020-2025)
 Table 13. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Key Players Head office and Products Offered
 Table 14. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
 Table 15. New Products and Potential Entrants
 Table 16. Mergers & Acquisitions, Expansion
 Table 17. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Region (2020-2025) & ($ millions)
 Table 18. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Region (2020-2025)
 Table 19. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue by Country/Region (2020-2025) & ($ millions)
 Table 20. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue Market Share by Country/Region (2020-2025)
 Table 21. Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Country (2020-2025) & ($ millions)
 Table 22. Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Country (2020-2025)
 Table 23. Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Type (2020-2025) & ($ millions)
 Table 24. Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Type (2020-2025)
 Table 25. Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Application (2020-2025) & ($ millions)
 Table 26. Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Application (2020-2025)
 Table 27. APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Region (2020-2025) & ($ millions)
 Table 28. APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Region (2020-2025)
 Table 29. APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Type (2020-2025) & ($ millions)
 Table 30. APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Application (2020-2025) & ($ millions)
 Table 31. Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Country (2020-2025) & ($ millions)
 Table 32. Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Country (2020-2025)
 Table 33. Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Type (2020-2025) & ($ millions)
 Table 34. Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Application (2020-2025) & ($ millions)
 Table 35. Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Region (2020-2025) & ($ millions)
 Table 36. Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Type (2020-2025) & ($ millions)
 Table 37. Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size by Application (2020-2025) & ($ millions)
 Table 38. Key Market Drivers & Growth Opportunities of Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO
 Table 39. Key Market Challenges & Risks of Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO
 Table 40. Key Industry Trends of Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO
 Table 41. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Forecast by Region (2026-2031) & ($ millions)
 Table 42. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share Forecast by Region (2026-2031)
 Table 43. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Forecast by Type (2026-2031) & ($ millions)
 Table 44. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Forecast by Application (2026-2031) & ($ millions)
 Table 45. Porton Pharma Solutions Details, Company Type, Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Area Served and Its Competitors
 Table 46. Porton Pharma Solutions Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
 Table 47. Porton Pharma Solutions Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 48. Porton Pharma Solutions Main Business
 Table 49. Porton Pharma Solutions Latest Developments
 Table 50. Lonza Group Ltd. Details, Company Type, Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Area Served and Its Competitors
 Table 51. Lonza Group Ltd. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
 Table 52. Lonza Group Ltd. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 53. Lonza Group Ltd. Main Business
 Table 54. Lonza Group Ltd. Latest Developments
 Table 55. BOC Sciences Details, Company Type, Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Area Served and Its Competitors
 Table 56. BOC Sciences Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
 Table 57. BOC Sciences Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 58. BOC Sciences Main Business
 Table 59. BOC Sciences Latest Developments
 Table 60. Asymchem Laboratories (Tianjin) Co., Ltd. Details, Company Type, Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Area Served and Its Competitors
 Table 61. Asymchem Laboratories (Tianjin) Co., Ltd. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
 Table 62. Asymchem Laboratories (Tianjin) Co., Ltd. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 63. Asymchem Laboratories (Tianjin) Co., Ltd. Main Business
 Table 64. Asymchem Laboratories (Tianjin) Co., Ltd. Latest Developments
 Table 65. PixelBiosciences GmbH Details, Company Type, Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Area Served and Its Competitors
 Table 66. PixelBiosciences GmbH Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
 Table 67. PixelBiosciences GmbH Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 68. PixelBiosciences GmbH Main Business
 Table 69. PixelBiosciences GmbH Latest Developments
 Table 70. 3PBIOVIAN Details, Company Type, Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Area Served and Its Competitors
 Table 71. 3PBIOVIAN Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
 Table 72. 3PBIOVIAN Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 73. 3PBIOVIAN Main Business
 Table 74. 3PBIOVIAN Latest Developments
 Table 75. Genscript Details, Company Type, Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Area Served and Its Competitors
 Table 76. Genscript Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
 Table 77. Genscript Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 78. Genscript Main Business
 Table 79. Genscript Latest Developments
 Table 80. MabPlex international) Details, Company Type, Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Area Served and Its Competitors
 Table 81. MabPlex international) Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
 Table 82. MabPlex international) Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 83. MabPlex international) Main Business
 Table 84. MabPlex international) Latest Developments
 Table 85. WuXi XDC Details, Company Type, Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Area Served and Its Competitors
 Table 86. WuXi XDC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
 Table 87. WuXi XDC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 88. WuXi XDC Main Business
 Table 89. WuXi XDC Latest Developments
 Table 90. ChemExpress Details, Company Type, Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Area Served and Its Competitors
 Table 91. ChemExpress Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
 Table 92. ChemExpress Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 93. ChemExpress Main Business
 Table 94. ChemExpress Latest Developments
 Table 95. Abzena Details, Company Type, Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Area Served and Its Competitors
 Table 96. Abzena Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Product Offered
 Table 97. Abzena Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 98. Abzena Main Business
 Table 99. Abzena Latest Developments


List of Figures
 Figure 1. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Report Years Considered
 Figure 2. Research Objectives
 Figure 3. Research Methodology
 Figure 4. Research Process and Data Source
 Figure 5. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth Rate (2020-2031) ($ millions)
 Figure 6. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
 Figure 7. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Sales Market Share by Country/Region (2024)
 Figure 8. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Sales Market Share by Country/Region (2020, 2024 & 2031)
 Figure 9. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Type in 2024
 Figure 10. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO in Commercial Use
 Figure 11. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market: Commercial Use (2020-2025) & ($ millions)
 Figure 12. Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO in Scientific Research
 Figure 13. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market: Scientific Research (2020-2025) & ($ millions)
 Figure 14. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Application in 2024
 Figure 15. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Revenue Market Share by Player in 2024
 Figure 16. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Region (2020-2025)
 Figure 17. Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2020-2025 ($ millions)
 Figure 18. APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2020-2025 ($ millions)
 Figure 19. Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2020-2025 ($ millions)
 Figure 20. Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2020-2025 ($ millions)
 Figure 21. Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Value Market Share by Country in 2024
 Figure 22. United States Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 23. Canada Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 24. Mexico Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 25. Brazil Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 26. APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Region in 2024
 Figure 27. APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Type (2020-2025)
 Figure 28. APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Application (2020-2025)
 Figure 29. China Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 30. Japan Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 31. South Korea Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 32. Southeast Asia Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 33. India Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 34. Australia Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 35. Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Country in 2024
 Figure 36. Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Type (2020-2025)
 Figure 37. Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Application (2020-2025)
 Figure 38. Germany Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 39. France Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 40. UK Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 41. Italy Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 42. Russia Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 43. Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Region (2020-2025)
 Figure 44. Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Type (2020-2025)
 Figure 45. Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share by Application (2020-2025)
 Figure 46. Egypt Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 47. South Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 48. Israel Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 49. Turkey Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 50. GCC Countries Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Growth 2020-2025 ($ millions)
 Figure 51. Americas Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 52. APAC Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 53. Europe Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 54. Middle East & Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 55. United States Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 56. Canada Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 57. Mexico Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 58. Brazil Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 59. China Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 60. Japan Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 61. Korea Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 62. Southeast Asia Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 63. India Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 64. Australia Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 65. Germany Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 66. France Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 67. UK Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 68. Italy Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 69. Russia Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 70. Egypt Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 71. South Africa Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 72. Israel Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 73. Turkey Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)
 Figure 74. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share Forecast by Type (2026-2031)
 Figure 75. Global Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size Market Share Forecast by Application (2026-2031)
 Figure 76. GCC Countries Antibody-Oligonucleotide Conjugates (AOC) Drug CDMO Market Size 2026-2031 ($ millions)

Companies Mentioned

Porton Pharma Solutions

Lonza Group Ltd.

BOC Sciences

Asymchem Laboratories (Tianjin) Co., Ltd.

PixelBiosciences GmbH

3PBIOVIAN

Genscript

MabPlex international)

WuXi XDC

ChemExpress

Abzena

Methodology

LP Information presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

Data Sourse

Primary Source

Secondary Source

Players/Suppliers

Journals and Periodicals

Industry Experts

Government Bodies

Distributors/Traders

Annual Reports

Opinion Leaders

Presentations

Front-line Staff